Press Releases
Relmada Sends Letter To Stockholders Highlighting Significant Progress In Value Creation Strategy Overseen By Board And Management Team
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Relmada Stockholders Vote the WHITE Proxy Card "FOR" Relmada's Director Nominees: Shreeram Agharkar and Maged Shenouda
Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team
U.S. Federal Court Issues Temporary Restraining Order Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
Relmada Therapeutics Announces Additional Information Regarding Positive Topline Results for Proof-of-Concept Study with BuTab
Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab
Relmada Therapeutics Files Federal Lawsuit Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern to Protect Interests of Relmada Stockholders
Relmada Therapeutics to Mail Letter to Stockholders Highlighting Laidlaw & Company's Questionable Business Practices and Conduct
Relmada Therapeutics to Present at LD Micro Main Event
Relmada Therapeutics Strengthens its Board of Directors with the Appointment of Maged Shenouda and Paul Kelly
